Current topics in medicinal chemistry · 2026
An Exosome-Liposome Hybrid Platform for Celastrol Delivery Enhances Anti-Tumor Efficacy in Hepatocellular Carcinoma.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chen Qiufang, Hu Junjie, Meng Jiang, Qu Yue, Zheng Guohua
Аннотация
INTRODUCTION: Celastrol (CEL), a promising agent for HCC treatment, is greatly restricted in clinical use because of its extremely low water solubility and high systemic toxicity. Novel delivery to enhance its therapeutic index is a key challenge.
METHODS: This study constructed a novel biomimetic hybrid nanodelivery system (CEL-Lipo-Exo) by the fusion of CEL-encapsulated liposome (CEL-Lipo) with exosomes derived from immortalized human mesenchymal stem cells. The in vitro and in vivo physicochemistry, anti-tumor efficacy, and toxicomechanistic properties of the nanoparticles were systematically characterized.
RESULTS: The resulting CEL-Lipo-Exo nanoparticle system showed uniform size distribution (100 nm), preserved essential features of exosomes, and high loading capacity (EE75%). In vitro, CELLipo- Exo more efficiently suppressed HCC cell growth and reduced cell migration and invasion, as well as caused greater apoptosis than free CEL and control liposomes. In vivo, the CEL-Lipo-Exo demonstrated the strongest inhibitory activities against tumors and completely abolished free CELinduced systemic toxicity.
DISCUSSION: The efficacy of converting a potent but cytotoxic natural compound to an effective nontoxic drug can be enhanced using the exosome-liposome hybrid concept. Utilizing the exosome shell as a biological camouflage, this platform surmounts the major barriers of celastrol for clinical application, thereby suggesting that biomimetic nanomedicine could be a solution for challenging drug candidates.
CONCLUSION: This CEL-Lipo-Exo nanoplatform is a very promising approach for the seeking of "safe and efficient" carriers of celastrol, suggesting an emerging target strategy for HCC therapy.
METHODS: This study constructed a novel biomimetic hybrid nanodelivery system (CEL-Lipo-Exo) by the fusion of CEL-encapsulated liposome (CEL-Lipo) with exosomes derived from immortalized human mesenchymal stem cells. The in vitro and in vivo physicochemistry, anti-tumor efficacy, and toxicomechanistic properties of the nanoparticles were systematically characterized.
RESULTS: The resulting CEL-Lipo-Exo nanoparticle system showed uniform size distribution (100 nm), preserved essential features of exosomes, and high loading capacity (EE75%). In vitro, CELLipo- Exo more efficiently suppressed HCC cell growth and reduced cell migration and invasion, as well as caused greater apoptosis than free CEL and control liposomes. In vivo, the CEL-Lipo-Exo demonstrated the strongest inhibitory activities against tumors and completely abolished free CELinduced systemic toxicity.
DISCUSSION: The efficacy of converting a potent but cytotoxic natural compound to an effective nontoxic drug can be enhanced using the exosome-liposome hybrid concept. Utilizing the exosome shell as a biological camouflage, this platform surmounts the major barriers of celastrol for clinical application, thereby suggesting that biomimetic nanomedicine could be a solution for challenging drug candidates.
CONCLUSION: This CEL-Lipo-Exo nanoplatform is a very promising approach for the seeking of "safe and efficient" carriers of celastrol, suggesting an emerging target strategy for HCC therapy.